Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan ireland limited - rivaroxaban - venous thromboembolism; pulmonary embolism; acute coronary syndrome; stroke; coronary artery disease; peripheral arterial disease; atrial fibrillation - aġenti antitrombotiċi - rivaroxaban mylan co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel or ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.  rivaroxaban mylan co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.  ------prevention of venous thromboembolism (vte) in adult patients undergoing elective hip or knee replacement surgery.  treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults. -------adults prevention of stroke and systemic embolism in adult   patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

accord healthcare s.l.u. - rivaroxaban - acute coronary syndrome; coronary artery disease; peripheral arterial disease; venous thromboembolism; stroke; atrial fibrillation; pulmonary embolism - aġenti antitrombotiċi - prevenzjoni ta ' l-thromboembolism venous (vte) fil-pazjenti adulti li għaddejjin minn elettiva għadma jew irkoppa sostituzzjoni kirurġija. trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti. (see section 4. 4 for haemodynamically unstable pe patients. trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti. (see section 4. 4 għall-emodinamikament instabbli pe pazjenti). adultsprevention of stroke and systemic embolism in adult patients with non valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. rivaroxaban accord, co administered with acetylsalicylic acid (asa) alone or with asa plus ticlopidine, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers (see sections 4. 3, 4. 4 u 5. rivaroxaban accord, co administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti. (see section 4. 4 for haemodynamically unstable pe patients. )paediatric populationtreatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

bayer ag - rivaroxaban - arthroplasty, replacement; venous thromboembolism - aġenti antitrombotiċi - xarelto, mogħti flimkien ma 'acetylsalicylic acid (asa) waħdu jew ma' asa flimkien ma ' clopidogrel jew ticlopidine, huwa indikat għall-prevenzjoni ta'avvenimenti aterotrombotiċi f'pazjenti adulti wara l-sindromu koronarju akut (acs) mal-bijomarkaturi kardijaċi għoljin. xarelto, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events. prevenzjoni ta ' l-thromboembolism venous (vte) fil-pazjenti adulti li għaddejjin minn elettiva għadma jew irkoppa sostituzzjoni kirurġija. trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti. adultsprevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment. paediatric population treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - andexanet alfa - relatati mal-mediċina l-effetti sekondarji u l-reazzjonijiet avversi - il-prodotti terapewtiċi l-oħra kollha - għall-pazjenti adulti kkurati b'dirett fattur xa (fxa) inibitur tal - (apixaban jew rivaroxaban) meta t-treġġigħ lura ta 'l-antikoagulazzjoni hu meħtieġ minħabba l-periklu għall-ħajja jew mhux ikkontrollat ta' fsada.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

akcea therapeutics ireland limited - inotersen sodium - amyloidosis - drogi oħra tas-sistema nervuża - it-trattament tal-fażi 1 jew l-istadju 2 polinewropatija f'pazjenti adulti b'ereditarji transthyretin amilojdożi (hattr).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

daiichi sankyo europe gmbh - edoxaban tosilate - stroke; venous thromboembolism - aġenti antitrombotiċi - prevenzjoni ta ' stroke u moћћ sistematiku fil-pazjenti adulti bl-fibrillation atrial nonvalvular (nvaf) b ' waħda jew aktar fatturi tar-riskju, bħal konġestiva, ipertensjoni, età ≥ 75 sena, id-diabete mellitus, stroke minn qabel jew ischaemic għaddiena attakk) tia). trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

berlin-chemie ag - edoxaban tosilate - stroke; venous thromboembolism - aġenti antitrombotiċi - prevenzjoni ta ' stroke u moћћ sistematiku fil-pazjenti adulti bl-fibrillation atrial nonvalvular (nvaf) b ' waħda jew aktar fatturi tar-riskju, bħal konġestiva, ipertensjoni, età ≥ 75 sena, id-diabete mellitus, stroke minn qabel jew ischaemic għaddiena attakk) tia). trattament ta 'trombożi f' vina fonda (dvt) u emboliżmu pulmonari (pe), u l-prevenzjoni tar-rikorrenti dvt u pe fl-adulti.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

mylan s.a.s - ritonavir - infezzjonijiet ta 'hiv - antivirali għal użu sistemiku - ritonavir huwa indikat flimkien ma 'aġenti antiretrovirali oħra għat-trattament ta' pazjenti infettati bl-hiv 1 (adulti u tfal ta '2 snin u aktar).

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

sanofi winthrop industrie - dronedarone - fibrilazzjoni atrijali - terapija kardijaka - multaq huwa indikat għall-manteniment tar-ritmu tas-sinus wara kardjoviżjoni b'suċċess f'pazjenti stabbli klinikament adulti b'fibrillazzjoni atrijali paroxysmal jew persistenti (af). minħabba l-profil ta 'sigurtà tiegħu, multaq għandu jiġi preskritt biss wara li jkunu ġew ikkunsidrati għażliet alternattivi ta' trattament. multaq m'għandux jingħata lill-pazjenti b'disfunzjoni sistolika tal-ventrikolu tax-xellug jew lill-pazjenti b'kurrenti jew preċedenti episodji ta ' insuffiċjenza tal-qalb.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

pfizer europe ma eeig - parecoxib sodium - uġigħ, wara l-operazzjoni - coxibs, antiinflammatory and antirheumatic products - għat-trattament għal żmien qasir ta 'uġigħ wara l-operazzjoni fl-adulti.